^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ABP 206 (nivolumab biosimilar)
i
Other names: ABP 206, ABP-206, ABP206
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Amgen
Drug class:
PD1 inhibitor
Related drugs:
1d
AREN1721: A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) (clinicaltrials.gov)
P2, N=15, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Nov 2026
Trial completion date
|
TFE3 (Transcription Factor Binding To IGHM Enhancer 3)
|
Opdivo (nivolumab) • Inlyta (axitinib) • ABP 206 (nivolumab biosimilar)
21d
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma (clinicaltrials.gov)
P3, N=256, Completed, Amgen | Active, not recruiting --> Completed
Trial completion
|
Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar)
22d
BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma (clinicaltrials.gov)
P2, N=43, Not yet recruiting, Mayo Clinic
New P2 trial
|
Opdivo (nivolumab) • gemcitabine • albumin-bound paclitaxel • ABP 206 (nivolumab biosimilar)
22d
Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial (clinicaltrials.gov)
P2, N=99, Recruiting, Emory University | Not yet recruiting --> Recruiting
Enrollment open
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
24d
DIAL: Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas (clinicaltrials.gov)
P2, N=54, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2025 --> Oct 2026
Trial completion date
|
ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • IRF4 (Interferon regulatory factor 4)
|
Opdivo (nivolumab) • varlilumab (CDX 1127) • ABP 206 (nivolumab biosimilar)
1m
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma (clinicaltrials.gov)
P3, N=620, Recruiting, Amgen | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2027 --> Jan 2028
Trial completion date • Trial primary completion date
|
Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar)
2ms
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers (clinicaltrials.gov)
P1, N=12, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2025 --> Sep 2026
Trial completion date • Checkpoint inhibition
|
BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
|
BRAF mutation
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • prednisone • ABP 206 (nivolumab biosimilar)
2ms
Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial (clinicaltrials.gov)
P2, N=82, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: May 2024 --> Jul 2025
Trial completion date • Trial primary completion date • Minimal residual disease
|
PD-L1 (Programmed death ligand 1)
|
Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar)
2ms
NRG-BN007: Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma (clinicaltrials.gov)
P2/3, N=159, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Sep 2026
Trial completion date • Tumor mutational burden
|
PD-L1 (Programmed death ligand 1) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
MGMT promoter methylation • IDH1 R132
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • temozolomide • ABP 206 (nivolumab biosimilar)
2ms
ETCTN-9844: Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer (clinicaltrials.gov)
P1, N=57, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2025 --> Sep 2026
Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Jingzhuda (entinostat) • ABP 206 (nivolumab biosimilar)
2ms
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (clinicaltrials.gov)
P2, N=6452, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
MSI (Microsatellite instability) • CD4 (CD4 Molecule)
|
Opdivo (nivolumab) • Herceptin (trastuzumab) • Mekinist (trametinib) • Xalkori (crizotinib) • Tagrisso (osimertinib) • Gilotrif (afatinib) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • Vitrakvi (larotrectinib) • sunitinib • Kadcyla (ado-trastuzumab emtansine) • Balversa (erdafitinib) • Mektovi (binimetinib) • adavosertib (AZD1775) • Truqap (capivasertib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • sapanisertib (CB-228) • ipatasertib (RG7440) • taselisib (GDC-0032) • omipalisib (GSK2126458) • ulixertinib (BVD-523) • Erivedge (vismodegib) • Trazimera (trastuzumab-qyyp) • Fakzynja (defactinib) • GSK2636771 • Paletan (pertuzumab biosimilar) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Pertuvia (pertuzumab biosimilar)
2ms
AIM-NIVO: Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer (clinicaltrials.gov)
P1, N=300, Recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2026 --> Mar 2028 | Trial primary completion date: Sep 2026 --> Mar 2028
Trial completion date • Trial primary completion date
|
MSI (Microsatellite instability) • IL2 (Interleukin 2)
|
Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar)
Share via
